About
Runs AI screening across eye disease and cardiovascular risk (an 'oculomics for primary care' motion) with a compact robotic fundus camera. Renamed from Eyetelligence in Oct 2023.
HQ: New York, USA (ops Melbourne)
Funding
$26M Series A (Sep 2025, Insight Partners-led, with 5 health systems)
Predecessor Eyetelligence raised $12M from Ascertain (Aegis/Northwell) in May 2023.